<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03820388</url>
  </required_header>
  <id_info>
    <org_study_id>909765</org_study_id>
    <nct_id>NCT03820388</nct_id>
  </id_info>
  <brief_title>Comparison of Etomidate Plus Propofol, Etomidate Alone on Induction of Anesthesia</brief_title>
  <official_title>Comparison of Etomidate Plus Propofol, Etomidate Alone on Induction of Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of Etomidate plus Propofol vs. Propofol or Etomidate alone during induction of
      anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison of Etomidate plus Propofol vs. Propofol or Etomidate alone during induction of
      anesthesia. The specific aims are testing patient reactions during induction, and in the
      post-anesthesia care unit (PACU).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Actual">July 13, 2018</completion_date>
  <primary_completion_date type="Actual">July 13, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients in 3 cohorts will be administered 30 second bolus by manual hand push</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>10 minutes after induction (intraoperative)</time_frame>
    <description>Blood Pressure Fluctuations during Induction; change measured in mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>10 minutes after induction (intraoperative)</time_frame>
    <description>Heart Rate changes during induction (Beats Per min)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain at injection site</measure>
    <time_frame>intraoperative</time_frame>
    <description>Pain on injection will be measured using 4 graded scale; 0 = no pain, 1 = verbal complaint of pain, 2 = withdrawal of arm, 3 = both verbal complaint and withdrawal of arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myoclonic movements</measure>
    <time_frame>intraoperative</time_frame>
    <description>The incidence and degree of myoclonic movements also recorded as follows: 0 = no myoclonic movements, 1 = minor myoclonic movements, 2 = moderate myoclonic movements, 3 = major myoclonic movements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative nausea and vomiting</measure>
    <time_frame>24 hours post-operation</time_frame>
    <description>Presence of post-operative nausea or vomiting (yes/no).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasoactive Agents Use</measure>
    <time_frame>30 minutes post-induction</time_frame>
    <description>Frequency of vasoactive agents use to treat adverse reactions of propofol/etomidate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation depth</measure>
    <time_frame>30 minutes post-induction</time_frame>
    <description>Sedation depth using bispectral index (BIS). BIS scores range from 0-100. A value of 0 indicates no EEG activity, 40-60 indicates an appropriate level of general anesthesia, and 90-100 is typical of a state of wakefulness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eyelash reflex disappear time</measure>
    <time_frame>1 minute post-induction</time_frame>
    <description>Time to disappearance of eyelash reflex after induction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intubation time</measure>
    <time_frame>5 minutes</time_frame>
    <description>Duration of orotracheal intubation.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Propofol Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol 2 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etomidate Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etomidate 0.3 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol plus Etomidate Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol 1 mg/kg plus Etomidate 0.15 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol 2mg/kg</intervention_name>
    <description>2 mg/kg</description>
    <arm_group_label>Propofol Group</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etomidate 0.3 mg/kg</intervention_name>
    <description>0.3 mg/kg</description>
    <arm_group_label>Etomidate Group</arm_group_label>
    <other_name>Amidate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol 1 mg/kg</intervention_name>
    <description>1 mg/kg Propofol</description>
    <arm_group_label>Propofol plus Etomidate Group</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etomidate 0.15 mg/kg</intervention_name>
    <description>0.15 mg/kg Etomidate</description>
    <arm_group_label>Propofol plus Etomidate Group</arm_group_label>
    <other_name>Amidate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for elective non-cardiac surgery

          -  ASA physical status of 2 or 3

          -  Age equal to or greater than 18 years old

        Exclusion Criteria:

          -  Adults unable to provide consent

          -  Age less than 18 years old

          -  Pregnant women

          -  Prisoners

          -  Difficult airway

          -  Morbid Obesity

          -  Preoperative sedation use

          -  Severe Cardiac, pulmonary and liver disease

          -  Hypotension and shock

          -  Emergency surgeries

          -  Allergy to propofol or etomidate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>January 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2019</study_first_posted>
  <last_update_submitted>January 25, 2019</last_update_submitted>
  <last_update_submitted_qc>January 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Etomidate</keyword>
  <keyword>Propofol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Etomidate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

